Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.
A new cell therapy approach has, in low-key fashion, attracted financing and the attention of big biopharma.
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.